Elevance Adds Former Cencora CEO Steve Collis to Board Amid Pharmacy Services Growth
ByAinvest
Thursday, Jul 31, 2025 3:10 pm ET1min read
COR--
Collis is currently the Executive Chairman of Cencora (formerly AmerisourceBergen), where he has held several key executive leadership positions. Notably, he served as President and CEO from 2011 to 2024, leading significant strategic transformations. His appointment to Elevance Health reflects the company's commitment to board evolution and sound governance [1].
Elevance Health's Carelon health services division, which includes pharmacy benefits manager CarelonRx, is expected to benefit from Collis's expertise. The division's revenue grew by 20% in Q2 2025, while operating profit rose by 8%. Elevance plans to continue investing in growth [1].
Ramey Peru, Chair of the Elevance Health Board of Directors, stated, "Steve brings a distinguished record of leadership, transformation, and operational excellence. His insights will support our continued focus on delivering high-quality care, driving innovation, and creating enduring value for the people and communities we serve" [1].
References:
[1] https://www.elevancehealth.com/newsroom/elevance-health-board-welcomes-steve-collis-as-new-director
ELV--
Elevance Health has named Steve Collis, former CEO of Cencora, to its board of directors. Collis has three decades of experience in the drug distribution industry and will serve on Elevance's audit and finance committees. His expertise is expected to be valuable for Elevance's Carelon health services division, which includes pharmacy benefits manager CarelonRx. The division's revenue was up 20% in Q2, while operating profit rose 8%. Elevance plans to continue investing in growth.
Elevance Health (NYSE: ELV) has announced the addition of Steve Collis to its board of directors, effective August 1. Collis, a seasoned global healthcare executive, brings three decades of experience in the drug distribution industry. He will serve on the Audit and Finance Committees, enhancing Elevance's financial oversight capabilities [1].Collis is currently the Executive Chairman of Cencora (formerly AmerisourceBergen), where he has held several key executive leadership positions. Notably, he served as President and CEO from 2011 to 2024, leading significant strategic transformations. His appointment to Elevance Health reflects the company's commitment to board evolution and sound governance [1].
Elevance Health's Carelon health services division, which includes pharmacy benefits manager CarelonRx, is expected to benefit from Collis's expertise. The division's revenue grew by 20% in Q2 2025, while operating profit rose by 8%. Elevance plans to continue investing in growth [1].
Ramey Peru, Chair of the Elevance Health Board of Directors, stated, "Steve brings a distinguished record of leadership, transformation, and operational excellence. His insights will support our continued focus on delivering high-quality care, driving innovation, and creating enduring value for the people and communities we serve" [1].
References:
[1] https://www.elevancehealth.com/newsroom/elevance-health-board-welcomes-steve-collis-as-new-director
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet